



## Verastem Oncology to Present at Upcoming Investor Conferences

August 27, 2025 at 7:00 AM EDT

BOSTON--(BUSINESS WIRE)--Aug. 27, 2025-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September:

- Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET
- H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference: Fireside chat on Monday, September 8 at 12:00 pm ET

A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company's website, <https://investor.verastem.com/events>. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

### About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit [www.verastem.com](http://www.verastem.com) and follow us on [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250827486598/en/): <https://www.businesswire.com/news/home/20250827486598/en/>

### For Investor and Media Inquiries:

Julissa Viana  
Vice President, Corporate Communications and Investor Relations  
[investors@verastem.com](mailto:investors@verastem.com) or  
[media@verastem.com](mailto:media@verastem.com)

Source: Verastem Oncology